12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TNF-Kinoid: Interim Phase II data

Neovacs said it will not enroll a second cohort of patients in the double-blind, international Phase II TNF-K-005 trial after interim data from the first cohort of 60 patients with moderate to severe CD who have failed >=1 anti-TNF therapy showed that 3 doses of 180 µg TNF-Kinoid did not significantly improve clinical remission rates, the primary endpoint, vs. placebo. The company did say that there was...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >